DK3604294T3 - Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter - Google Patents

Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter Download PDF

Info

Publication number: DK3604294T3
Authority: DK; Denmark
Prior art keywords: chinase; activities; compositions; compounds; egfr mutant
Prior art date: 2014-10-13

Application number

DK19196713.2T

Other languages

English (en)

Inventor

Byung-Chul Suh

Paresh Devidas Salgaonkar

Jaekyoo Lee

Jong Sung Koh

Ho-Juhn Song

In Yong Lee

Jaesang Lee

Dong Sik Jung

Jung-Ho Kim

Se-Won Kim

Original Assignee

Yuhan Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-13

Filing date

2015-10-13

Publication date

2021-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3604294(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-13 Application filed by Yuhan Corp filed Critical Yuhan Corp

2021-06-28 Application granted granted Critical

2021-06-28 Publication of DK3604294T3 publication Critical patent/DK3604294T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK19196713.2T 2014-10-13 2015-10-13 Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter DK3604294T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462063394P	2014-10-13	2014-10-13
EP15850314.4A EP3207035B1 (en)	2014-10-13	2015-10-13	Compounds and compositions for modulating egfr mutant kinase activities

Publications (1)

Publication Number	Publication Date
DK3604294T3 true DK3604294T3 (da)	2021-06-28

Family

ID=55654993

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK19196713.2T DK3604294T3 (da)	2014-10-13	2015-10-13	Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter
DK15850314.4T DK3207035T3 (da)	2014-10-13	2015-10-13	Forbindelser og sammensætninger til modulering af egfr- mutantkinaseaktiviteter
DK21171619.6T DK3929190T3 (da)	2014-10-13	2015-10-13	Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK15850314.4T DK3207035T3 (da)	2014-10-13	2015-10-13	Forbindelser og sammensætninger til modulering af egfr- mutantkinaseaktiviteter
DK21171619.6T DK3929190T3 (da)	2014-10-13	2015-10-13	Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter

Country Status (27)

Country	Link
US (1)	US9593098B2 (da)
EP (4)	EP4421069A1 (da)
JP (3)	JP6524221B2 (da)
KR (5)	KR20240074820A (da)
CN (2)	CN111686110B (da)
AU (1)	AU2015331166B2 (da)
BR (1)	BR112017007769B1 (da)
CA (1)	CA2962914C (da)
CY (2)	CY1122737T1 (da)
DK (3)	DK3604294T3 (da)
ES (3)	ES3009926T3 (da)
FI (1)	FI3929190T3 (da)
HR (3)	HRP20250213T1 (da)
HU (2)	HUE048006T2 (da)
LT (3)	LT3604294T (da)
MX (3)	MX385942B (da)
NZ (1)	NZ730012A (da)
PH (1)	PH12017500488A1 (da)
PL (2)	PL3604294T3 (da)
PT (3)	PT3604294T (da)
RS (3)	RS61865B1 (da)
RU (1)	RU2727700C2 (da)
SG (1)	SG11201701960XA (da)
SI (2)	SI3207035T1 (da)
SM (3)	SMT202000059T1 (da)
TW (2)	TWI664173B (da)
WO (1)	WO2016060443A2 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS61865B1 (sr) *	2014-10-13	2021-06-30	Yuhan Corp	Jedinjenja i kompozicije za moduliranje aktivnosti egfr mutant kinaze
WO2017044434A1 (en)	2015-09-11	2017-03-16	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
TWI726968B (zh)	2016-01-07	2021-05-11	開曼群島商Ｃｓ醫藥技術公司	Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
US10513509B2 (en) *	2016-05-26	2019-12-24	Recurium Ip Holdings, Llc	EGFR inhibitor compounds
KR102030886B1 (ko) *	2016-09-23	2019-10-10	재단법인 대구경북첨단의료산업진흥재단	신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) *	2017-04-21	2019-07-17	Yuhan Corp	Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
JP7028900B2 (ja) *	2017-06-13	2022-03-02	ベイジンアダマドルバイオテクノロジーリミテッドライアビリティカンパニー	アミノピリミジン化合物、その調製方法、およびその使用
JP7216704B2 (ja) *	2017-07-28	2023-02-01	ユハンコーポレーション	アミノピリミジン誘導体の合成に有用な新規中間体、それを調製するためのプロセス、及びそれを使用してアミノピリミジン誘導体を調製するためのプロセス
CA3070069C (en) *	2017-07-28	2024-02-20	Yuhan Corporation	Improved process for preparing aminopyrimidine derivatives
DK3658547T3 (da) *	2017-07-28	2023-10-16	Yuhan Corp	Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
EP3653622B1 (en) *	2017-08-30	2022-12-28	Shenzhen TargetRx, Inc.	Aminopyrimidine compound and composition comprising same and use thereof
CN108017633A (zh) *	2018-01-30	2018-05-11	天津大学	N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN108047207A (zh) *	2018-01-30	2018-05-18	天津大学	N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
KR20200043618A (ko) *	2018-10-18	2020-04-28	주식회사유한양행	아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
US20220048891A1 (en) *	2018-12-21	2022-02-17	Shenzhen Targetrx, Inc.	Aminopyrimidine compound used for inhibiting activity of protein kinase
MA55089A (fr)	2019-02-26	2022-01-05	Janssen Biotech Inc	Traitements combinés et stratification des patients avec des anticorps bispécifiques anti-egfr/c-met
US12157730B2 (en)	2019-03-19	2024-12-03	Voronoi Inc.	Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
BR112021018704B1 (pt)	2019-03-19	2023-01-10	Voronoi Inc.	Derivado de heteroarila, método para produção do mesmo, e composição farmacêutica compreendendo a mesma como componente eficaz
MA55508A (fr)	2019-03-29	2022-02-09	Astrazeneca Ab	Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
CN111747931A (zh) *	2019-03-29	2020-10-09	深圳福沃药业有限公司	用于治疗癌症的氮杂芳环酰胺衍生物
WO2020230091A1 (en)	2019-05-14	2020-11-19	Janssen Biotech, Inc.	Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en)	2019-05-14	2023-12-26	Yuhan Corporation	Therapies with 3rd generation EGFR tyrosine kinase inhibitors
CN110128354A (zh) *	2019-06-20	2019-08-16	大连大学	一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko)	2019-09-16	2021-03-24	제이투에이치바이오텍 (주)	Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
US20210161897A1 (en)	2019-11-12	2021-06-03	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20220130190A (ko)	2020-01-20	2022-09-26	아스트라제네카 아베	암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
JOP20220184A1 (ar)	2020-02-12	2023-01-30	Janssen Biotech Inc	علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh)	2020-04-14	2022-03-01	美商健生生物科技公司	包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en)	2020-05-27	2021-12-02	Astrazeneca Ab	EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) *	2020-06-08	2021-12-15	주식회사 종근당	카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
US20230321087A1 (en)	2020-09-14	2023-10-12	Janssen Pharmaceutica Nv	Fgfr inhibitor combination therapies
TW202227425A (zh) *	2020-09-18	2022-07-16	南韓商沃若諾伊生物公司	雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
TWI867047B (zh) *	2020-09-18	2024-12-21	南韓商沃若諾伊公司	雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
WO2022131741A1 (ko) *	2020-12-14	2022-06-23	보로노이바이오 주식회사	아이소옥사졸리딘 유도체 화합물 및 이의 용도
EP4335847A1 (en) *	2021-05-07	2024-03-13	Voronoi Inc.	Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
KR102607051B1 (ko) *	2021-05-17	2023-11-30	보로노이 주식회사	헤테로아릴 유도체 화합물 및 이의 용도
US20240270733A1 (en)	2021-06-01	2024-08-15	Hangzhou Solipharma Co., Ltd.	Hydrate form of lazertinib mesylate, preparation method thereof and use thereof
KR102685187B1 (ko)	2021-10-15	2024-07-16	제이투에이치바이오텍 (주)	Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh)	2022-02-07	2023-11-01	美商健生生物科技公司	用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
JP2025510910A (ja)	2022-03-31	2025-04-15	アストラゼネカ・アクチエボラーグ	癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤
IL316475A (en)	2022-04-28	2024-12-01	Astrazeneca Ab	Heterocyclic Condensed Compounds and Their Use in Cancer Therapy
US20240116926A1 (en)	2022-04-28	2024-04-11	Astrazeneca Ab	Heteroaromatic compounds
WO2023209090A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their use in the treatment of cancer
EP4543920A1 (en)	2022-06-27	2025-04-30	Astrazeneca AB	Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN119654152A (zh)	2022-07-08	2025-03-18	阿斯利康(瑞典)有限公司	与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
WO2024096624A1 (en) *	2022-11-03	2024-05-10	Voronoi Inc.	Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor
WO2024241273A1 (en)	2023-05-23	2024-11-28	Janssen Biotech, Inc.	Methods for treatment of non-small cell lung cancer (nsclc)
CN116655600A (zh) *	2023-05-23	2023-08-29	江南大学	一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
WO2025017409A1 (en)	2023-07-14	2025-01-23	Janssen Biotech, Inc.	Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025052273A1 (en)	2023-09-05	2025-03-13	Janssen Biotech, Inc.	Methods of treating non-small cell lung cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20030024659A (ko) *	2000-02-17	2003-03-26	암겐 인코포레이티드	키나제 억제제
PL377795A1 (pl) *	2002-11-28	2006-02-20	Schering Aktiengesellschaft	Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
JP4428565B2 (ja)	2004-10-05	2010-03-10	東京エレクトロン株式会社	処理液塗布装置
US20070072894A1 (en)	2005-03-24	2007-03-29	Kempf J V	Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja)	2005-07-13	2012-08-22	Ｎｔｎ株式会社	グリース組成物および該グリース封入転がり軸受
MX2008002383A (es)	2005-08-25	2008-03-18	Hoffmann La Roche	Pirazol fusionado como inhibidores de proteinas cinasas activadas por mitogenos p38.
JP2007117465A (ja)	2005-10-28	2007-05-17	Sharp Corp	集塵器およびそれを備えた電気掃除機
GB2450046B (en)	2006-03-29	2011-03-09	Kt Freetel Co Ltd	Digital device and method for providing additional service by using the same
EP2001480A4 (en)	2006-03-31	2011-06-15	Abbott Lab	Indazole CONNECTIONS
KR101955914B1 (ko) *	2008-06-27	2019-03-11	셀젠 카르 엘엘씨	헤테로아릴 화합물 및 이의 용도
EP2440559B1 (en) *	2009-05-05	2018-01-10	Dana-Farber Cancer Institute, Inc.	Egfr inhibitors and methods of treating disorders
SG10201407453TA (en) *	2009-11-13	2014-12-30	Genosco	Kinase inhibitors
AU2012221925B2 (en) *	2011-02-25	2016-05-05	Yuhan Corporation	Diaminopyrimidine derivatives and processes for the preparation thereof
EP3686194B1 (en) *	2011-07-27	2021-09-15	Astrazeneca AB	2-(2,4,5-substituted-anilino)pyrimidine compounds
AU2013209586B2 (en)	2012-01-20	2017-08-17	Genosco	Substituted pyrimidine compounds and their use as SYK inhibitors
WO2014040555A1 (zh) *	2012-09-12	2014-03-20	山东亨利医药科技有限责任公司	作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) *	2013-04-09	2015-02-17	Principia Biopharma Inc.	Tyrosine kinase inhibitors
WO2015025197A1 (en) *	2013-08-22	2015-02-26	Jubilant Biosys Limited	Substituted pyrimidine compounds, compositions and medicinal applications thereof
CN111892579B (zh)	2014-06-12	2023-07-25	上海艾力斯医药科技股份有限公司	一类激酶抑制剂
RS61865B1 (sr) *	2014-10-13	2021-06-30	Yuhan Corp	Jedinjenja i kompozicije za moduliranje aktivnosti egfr mutant kinaze
CN104788427B (zh) *	2015-02-05	2017-05-31	上海泓博智源医药股份有限公司	3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

2015
- 2015-10-13 RS RS20210608A patent/RS61865B1/sr unknown
- 2015-10-13 CA CA2962914A patent/CA2962914C/en active Active
- 2015-10-13 SG SG11201701960XA patent/SG11201701960XA/en unknown
- 2015-10-13 KR KR1020247013986A patent/KR20240074820A/ko active Pending
- 2015-10-13 LT LTEP19196713.2T patent/LT3604294T/lt unknown
- 2015-10-13 SM SM20200059T patent/SMT202000059T1/it unknown
- 2015-10-13 ES ES21171619T patent/ES3009926T3/es active Active
- 2015-10-13 AU AU2015331166A patent/AU2015331166B2/en active Active
- 2015-10-13 KR KR1020217002019A patent/KR102487451B1/ko active Active
- 2015-10-13 EP EP24166947.2A patent/EP4421069A1/en active Pending
- 2015-10-13 ES ES19196713T patent/ES2879474T3/es active Active
- 2015-10-13 EP EP21171619.6A patent/EP3929190B1/en active Active
- 2015-10-13 LT LTEP21171619.6T patent/LT3929190T/lt unknown
- 2015-10-13 DK DK19196713.2T patent/DK3604294T3/da active
- 2015-10-13 EP EP19196713.2A patent/EP3604294B1/en active Active
- 2015-10-13 SI SI201531055T patent/SI3207035T1/sl unknown
- 2015-10-13 PT PT191967132T patent/PT3604294T/pt unknown
- 2015-10-13 ES ES15850314T patent/ES2770058T3/es active Active
- 2015-10-13 RU RU2017116598A patent/RU2727700C2/ru active
- 2015-10-13 TW TW104133539A patent/TWI664173B/zh active
- 2015-10-13 TW TW108118264A patent/TWI730331B/zh active
- 2015-10-13 WO PCT/KR2015/010784 patent/WO2016060443A2/en active Application Filing
- 2015-10-13 PL PL19196713T patent/PL3604294T3/pl unknown
- 2015-10-13 DK DK15850314.4T patent/DK3207035T3/da active
- 2015-10-13 BR BR112017007769-8A patent/BR112017007769B1/pt active IP Right Grant
- 2015-10-13 HU HUE15850314A patent/HUE048006T2/hu unknown
- 2015-10-13 KR KR1020237000623A patent/KR102662358B1/ko active Active
- 2015-10-13 PT PT158503144T patent/PT3207035T/pt unknown
- 2015-10-13 FI FIEP21171619.6T patent/FI3929190T3/fi active
- 2015-10-13 KR KR1020177012969A patent/KR102073854B1/ko active Active
- 2015-10-13 MX MX2020002168A patent/MX385942B/es unknown
- 2015-10-13 NZ NZ730012A patent/NZ730012A/en unknown
- 2015-10-13 JP JP2017519685A patent/JP6524221B2/ja active Active
- 2015-10-13 SM SM20210266T patent/SMT202100266T1/it unknown
- 2015-10-13 EP EP15850314.4A patent/EP3207035B1/en active Active
- 2015-10-13 KR KR1020207002949A patent/KR102208775B1/ko active Active
- 2015-10-13 DK DK21171619.6T patent/DK3929190T3/da active
- 2015-10-13 RS RS20200101A patent/RS59900B1/sr unknown
- 2015-10-13 CN CN202010422259.0A patent/CN111686110B/zh active Active
- 2015-10-13 PL PL15850314T patent/PL3207035T3/pl unknown
- 2015-10-13 PT PT211716196T patent/PT3929190T/pt unknown
- 2015-10-13 HR HRP20250213TT patent/HRP20250213T1/hr unknown
- 2015-10-13 MX MX2017003181A patent/MX2017003181A/es active IP Right Grant
- 2015-10-13 SM SM20250069T patent/SMT202500069T1/it unknown
- 2015-10-13 CN CN201580055717.9A patent/CN106795144B/zh active Active
- 2015-10-13 US US14/881,930 patent/US9593098B2/en active Active
- 2015-10-13 RS RS20250168A patent/RS66529B1/sr unknown
- 2015-10-13 SI SI201531611T patent/SI3604294T1/sl unknown
- 2015-10-13 LT LTEP15850314.4T patent/LT3207035T/lt unknown
- 2015-10-13 HU HUE19196713A patent/HUE054848T2/hu unknown
2017
- 2017-03-10 MX MX2021010761A patent/MX2021010761A/es unknown
- 2017-03-14 PH PH12017500488A patent/PH12017500488A1/en unknown
2019
- 2019-04-26 JP JP2019085608A patent/JP6754864B2/ja active Active
2020
- 2020-02-07 HR HRP20200201TT patent/HRP20200201T1/hr unknown
- 2020-02-17 CY CY20201100143T patent/CY1122737T1/el unknown
- 2020-08-24 JP JP2020141205A patent/JP2020196740A/ja not_active Withdrawn
2021
- 2021-06-14 HR HRP20210949TT patent/HRP20210949T1/hr unknown
- 2021-07-26 CY CY20211100670T patent/CY1124359T1/el unknown

Also Published As

Publication number	Publication date
TWI730331B (zh)	2021-06-11
HRP20200201T1 (hr)	2020-05-15
MX2021010761A (es)	2022-06-09
JP6524221B2 (ja)	2019-06-05
RU2017116598A (ru)	2018-11-21
PT3207035T (pt)	2020-02-19
CN106795144A (zh)	2017-05-31
RU2020123547A (ru)	2020-08-18
KR102073854B1 (ko)	2020-02-05
KR20170066650A (ko)	2017-06-14
CN106795144B (zh)	2020-06-16
CA2962914A1 (en)	2016-04-21
BR112017007769B1 (pt)	2023-10-10
PL3207035T3 (pl)	2020-06-01
JP2017530999A (ja)	2017-10-19
CA2962914C (en)	2018-10-23
TW201938553A (zh)	2019-10-01
KR20230010836A (ko)	2023-01-19
SI3604294T1 (sl)	2021-08-31
MX385942B (es)	2025-03-18
PH12017500488A1 (en)	2017-07-31
EP3207035A2 (en)	2017-08-23
TWI664173B (zh)	2019-07-01
LT3207035T (lt)	2020-02-25
NZ730012A (en)	2019-06-28
LT3929190T (lt)	2025-02-25
DK3929190T3 (da)	2025-02-24
US9593098B2 (en)	2017-03-14
TW201619150A (zh)	2016-06-01
RU2017116598A3 (da)	2018-11-21
CN111686110A (zh)	2020-09-22
KR102208775B1 (ko)	2021-01-28
SMT202500069T1 (it)	2025-03-12
US20160102076A1 (en)	2016-04-14
RS59900B1 (sr)	2020-03-31
CY1122737T1 (el)	2021-03-12
PT3604294T (pt)	2021-07-29
KR20210011068A (ko)	2021-01-29
SMT202100266T1 (it)	2021-07-12
EP3929190A1 (en)	2021-12-29
EP3207035A4 (en)	2018-03-14
KR20240074820A (ko)	2024-05-28
EP3929190B1 (en)	2024-12-25
CY1124359T1 (el)	2022-07-22
EP4421069A1 (en)	2024-08-28
DK3207035T3 (da)	2020-01-27
EP3604294B1 (en)	2021-05-05
RU2727700C2 (ru)	2020-07-23
RS61865B1 (sr)	2021-06-30
BR112017007769A2 (pt)	2018-01-16
KR20200014944A (ko)	2020-02-11
HUE054848T2 (hu)	2021-09-28
HUE048006T2 (hu)	2020-05-28
CN111686110B (zh)	2023-06-16
FI3929190T3 (fi)	2025-02-28
JP2019163277A (ja)	2019-09-26
MX2020002168A (es)	2021-09-07
RS66529B1 (sr)	2025-03-31
AU2015331166A1 (en)	2017-03-30
EP3604294A1 (en)	2020-02-05
PT3929190T (pt)	2025-02-19
SG11201701960XA (en)	2017-04-27
HRP20210949T1 (hr)	2021-09-03
AU2015331166B2 (en)	2018-04-26
SMT202000059T1 (it)	2020-03-13
ES3009926T3 (en)	2025-03-31
EP3207035B1 (en)	2019-11-20
MX2017003181A (es)	2017-07-20
WO2016060443A3 (en)	2016-06-23
ES2770058T3 (es)	2020-06-30
KR102662358B1 (ko)	2024-04-30
JP2020196740A (ja)	2020-12-10
WO2016060443A2 (en)	2016-04-21
HRP20250213T1 (hr)	2025-04-25
JP6754864B2 (ja)	2020-09-16
KR102487451B1 (ko)	2023-01-11
LT3604294T (lt)	2021-07-26
ES2879474T3 (es)	2021-11-22
SI3207035T1 (sl)	2020-04-30
PL3604294T3 (pl)	2021-11-02

Publication	Publication Date	Title
DK3604294T3 (da)	2021-06-28	Forbindelser og sammensætninger til modulering af egfr-mutantkinaseaktiviteter
DK3137605T3 (da)	2020-12-14	Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3125927T3 (da)	2021-04-19	Fremgangsmåder og sammensætninger til immunmodulering
DK3092256T3 (da)	2022-06-20	Forbindelser og sammensætninger til immunterapi
DK3283080T3 (da)	2020-04-06	Sammensætninger til modulation af c9orf72-ekspression
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3134130T3 (da)	2019-08-26	Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3119408T3 (da)	2020-03-16	Overfladereageret calciumkarbonat til desensibilisering af tænder
DK3628732T3 (da)	2023-05-30	Transposasesammensætninger til reduktion af insertionsbias
DK3119888T3 (da)	2021-09-06	Sammensætninger til at modulere ataxin-2-ekspression
DK3102555T3 (da)	2021-08-09	Sammensætninger af forbindelser og anvendelser deraf
DK3393655T3 (da)	2021-03-15	Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK2924093T3 (da)	2018-01-29	Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
DK3143026T3 (da)	2024-09-30	Forbindelser og sammensætninger til induktion af chondrogenese
DK3129779T3 (da)	2020-09-07	Fremgangsmåder og sammensætninger til påvisning af fejlfoldede proteiner
DK3520591T3 (da)	2020-12-21	Fremgangsmåde til spredning af gødningsmidler
DK3110446T3 (da)	2022-02-28	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3148517T3 (da)	2021-07-26	Sammensætninger og fremgangsmåder til fremme af knogledannelse
DK3431460T3 (da)	2021-05-10	Ny formulering og fremgangsmåde til syntese
DK3122349T3 (da)	2022-02-14	Sammensætninger til behandling af autodigestion
DK2910535T3 (da)	2019-07-01	Sammensætning til anvendelse af ekspanderet perlit
DK3113774T3 (da)	2022-03-07	Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf
DK3097081T3 (da)	2018-01-29	Fremgangsmåde til fremstilling af 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carbaldehyder og 1-alkyl-3-difluormethyl-5-fluor-1h-pyrazol-4-carboxylater